Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research

Affiliations

¹ School of Cancer Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
² Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK.
³ Department of Histopathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham NG5 1PB, UK.
⁴ Department of Clinical Oncology, Nottingham University Hospitals NHS Trust, City Hospital, Nottingham NG5 1PB, UK.
⁵ Division of Imaging and Technology, Medical Research Institute, Ninewells Hospital Medical School, University of Dundee, Dundee DD1 9SY, UK.
⁶ Department of Academic Oncology, School of Molecular Medical Sciences, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham NG5 1PB, UK.
⁷ Centre for Tumour Biology, Barts Cancer Institute-a Cancer Research UK Centre of Excellence, Queen Mary University of London, London EC1M 6BQ, UK.

D Rea et al. Br J Cancer. 2015.

. 2015 Apr 28;112(9):1613-5.

doi: 10.1038/bjc.2015.115. Epub 2015 Mar 31.

¹ School of Cancer Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
² Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK.
³ Department of Histopathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham NG5 1PB, UK.
⁴ Department of Clinical Oncology, Nottingham University Hospitals NHS Trust, City Hospital, Nottingham NG5 1PB, UK.
⁵ Division of Imaging and Technology, Medical Research Institute, Ninewells Hospital Medical School, University of Dundee, Dundee DD1 9SY, UK.
⁶ Department of Academic Oncology, School of Molecular Medical Sciences, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham NG5 1PB, UK.
⁷ Centre for Tumour Biology, Barts Cancer Institute-a Cancer Research UK Centre of Excellence, Queen Mary University of London, London EC1M 6BQ, UK.

No abstract available

References

1. Dall BJ, Vinnicombe S, Gilbert FJ. Reporting and management of breast lesions detected using MRI. Clin Radiol. 2011;66 (12:1120–1128. - PubMed
1. Dawood S, Cristofanilli M.2011Inflammatory breast cancer: what progress have we made Oncology (Williston Park) 25(3264–270.273. - PubMed
1. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22 (3:515–523. - PMC - PubMed
1. Groheux D, Giacchetti S, Delord M, Hindie E, Vercellino L, Cuvier C, Toubert ME, Merlet P, Hennequin C, Espie M. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med. 2013;54 (1:5–11. - PubMed
1. Gunhan-Bilgen I, Ustun EE, Memis A. Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. Radiology. 2002;223 (3:829–838. - PubMed